MSB

2.11%

97.0¢ mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-30

First 30 Last

Share
Profile

Follow
tubbyguts

3,346 Posts.

269

02/10/20

13:01

Post #: 47808286
Share

Originally posted by Tiggietrain1719: ↑

My confusion about this meeting is that all of the evidence that MSB have, has already been presented, voted on with an overwhelming majority by ODAC and still knocked back. What more can they present or do to overturn it?

Expand

Another trial and refined potency metrics

Originally posted by MelbourneBoy: ↑

If you look at this situation from both a scientific & commercial perspective, a fundamental question of the FDA is this:

Can you prove that every patient gets a uniform dose and that the dose is equally effective?

Now from one side you could say that if 70% of patients live when only 15% did previously, does it matter? More people (kids in this case) when there is no real alternative.

However, consider this:

What if the 30% who died did so because the dose was not as effective as it was meant to be?
Some patients would then have had a reduced chance of survival and them, their families or their insurers have paid for a treatment that was less effective than it otherwise may have been.

This is a pretty big question and central to the work Mesoblast now needs to do.

They either need to show the FDA how their methods of uniformity and dose are appropriate, or find a way to modify their methods to better reflect FDA custom and practise.

Note: I am a holder, I am very supportive of the company, but I am also a TGA license holder here in Australia, so do have some insight into how these regulators work.

Good luck to everyone. Lets hope updates aren't too far away.

Expand

bingo. Pay attention to this guy

MSB Price at posting: $3.37 Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

SGA

Sarytogan promises good returns on Kazakhstan project, but the market is uncertain

KCC

Kincora partners with Woomera to advance Mongolian copper-gold play

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

CKA

Cokal plans to kick off unexpected underground mine in Indonesia

There are more pages in this discussion • 988 more messages in this thread...

First 30 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 97.0¢		Change 0.020(2.11%)		Mkt cap ! $1.098B

Open	High	Low	Value	Volume
94.5¢	98.0¢	93.5¢	$3.680M	3.810M

Buyers (Bids)

No.	Vol.	Price($)
5	149921	96.5¢

Sellers (Offers)

Price($)	Vol.	No.
97.5¢	60000	1

View Market Depth

No.	Vol.	Price($)
5	149921	0.965
5	66704	0.960
5	98366	0.955
4	43570	0.950
4	130698	0.945

Price($)	Vol.	No.
0.975	60000	1
0.980	224951	2
0.985	227011	7
0.990	214282	8
0.995	68432	3

Last trade - 16.10pm 12/08/2024 (20 minute delay)

MSB (ASX) Chart

MSB to dispute FDA finding in Type A meeting, page-30

Sarytogan promises good returns on Kazakhstan project, but the market is uncertain

Kincora partners with Woomera to advance Mongolian copper-gold play

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

Cokal plans to kick off unexpected underground mine in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB to dispute FDA finding in Type A meeting, page-30

Top Stories

Sarytogan promises good returns on Kazakhstan project, but the market is uncertain

Kincora partners with Woomera to advance Mongolian copper-gold play

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

Cokal plans to kick off unexpected underground mine in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News